Kornimate/medical-research-clean huggingface dataset:
the effect of a case-finding app on the detection rate of atrial fibrillation in primary care patients

Conditions: Atrial Fibrillation Paroxysmal

Summary: atrial fibrillation is a cardiac arrhythmia commonly encountered in a primary care setting. current screening is limited to pulse palpation and ecg confirmation when an irregular pulse is found. paroxysmal atrial fibrillation will, however, still be difficult to pick up. with the advent of smartphones, screening could be more cost-efficient by making use of simple applications, lowering the need for intensive screening to discover (paroxysmal) atrial fibrillation. this cluster randomized trial will examine the effect of using a smartphone-based application such as fibricheck® on the detection rate of atrial fibrillation in a flemish general practice population. this study will be conducted in 22 primary care practices across the flanders region of belgium and will last 12 months. patients above 65 years of age will be divided in control and intervention groups on the practice level. the control group will be subjected to standard opportunistic screening only, while the intervention group will be prescribed the fibricheck® app on top of this opportunistic screening. the difference in detection rate between control and intervention groups will be calculated at the end of the study. the investigators will use the online platform intego for pseudonymized data collection and analysis, and risk calculation. smartphone applications might offer a way to cost-effectively screen for (paroxysmal) atrial fibrillation in a primary care setting. this could open the door for the update of future screening guidelines.


Eligibility criteria:
inclusion criteria: 1. the patient is 65 years or older. 2. the patient has an electronic medical record (emr) in the practice. this emr contains all the patient information, for instance regarding medical history and medication and is managed by the general practitioner. 3. if the patient will be prescribed the fibricheck® app, he/she signs the relevant patient consent form exclusion criteria: 1. the patient has already been diagnosed with af. 2. the patient is already under anticoagulant therapy. 3. the patient has a pacemaker. active pacing during measurements influences the results obtained with the fibricheck® app (26). 4. the patient is unable to use the fibricheck® application independently due to cognitive disorders, functional limitations, visual impairments...

Keywords: atrial fibrillation screening fibricheck case finding
microbiological study on maxillary complete dentures of two different materials

Conditions: Denture Stomatitis

Summary: cross over design the investigator divide participants to two groups group (a) will receive rapid heat cured denture base material and group (b) will receive the acrylic denture modified by titanium dioxide nanoparticles and after washout period alternatively group (a) will receive the acrylic denture modified by titanium dioxide nanoparticles and group (b) will receive rapid heat cured denture base material the investigator will take swaps from dentures to count the anaerobic bacteria.

first the investigator will take primary impression, and pour it obtain primary cast, then will fabricate special tray an take secondary impression and obtain master cast after that duplication of master cast will be done the investigator will make cross over design.and divide participants to two groups group (a) will receive rapid heat cured denture base material and group (b) will receive the acrylic denture modified by titanium dioxide nanoparticle and after washout period alternatively group (a) will receive the acrylic denture modified by titanium dioxide nanoparticle and group (b) will receive rapid heat cured denture base material the investigator will take swaps from the different dentures to count the anaerobic bacteria by (cfu).

Eligibility criteria:
inclusion criteria: 1. completely edentulous maxillary arch and partially dentate mandibular arch with adequate interarch space. 2. the edentulous ridges should be covered by firm healthy mucosa. 3-angle class i maxillomandibular relation. 4-healthy and cooperative patient exclusion criteria: 1. patients with bad habits as severe clenching or bruxism, drug or alcohol addiction, moderate or heavy smoking (greater than 10 cigarettes per day). 2. previous history of radiotherapy or chemotherapy. 3. any skeletal problem dictates surgical intervention
stem cells therapy for corneal blindness

Conditions: Corneal Injuries; Corneal Burns; Corneal Scars and Opacities

Summary: this is a investigative initiated, comparative pilot clinical trial to ascertain the safety of application of ex-vivo cultivated limbal stem cells in human eyes for treating different superficial corneal pathologies. pre-clinical work in murine models have already demonstrated efficacy of this technique in curing murine corneal pathologies.

in this prospective interventional study patients with superficial corneal pathologies like scars, ulcers and burns will undergo a surgical procedure. limbal ring from a cadaveric donor tissue, which is therapeutically accepted and serologically tested, is collected. this tissue will then be cultivated in the stem cell biology laboratory using standardized culture technique. briefly the limbal tissue will be cut up into small pieces and digested overnight using an enzyme (collagenase l). the cells obtained from the digest will be cultured on a petri-dish using 2% serum and growth factors. the cultured cells will be passaged three times to remove all epithelial cells from the culture. in the second procedure, the central corneal epithelium will be removed using a surgical sponge. 0.1ml of stromal cells in a concentration of 5x10\^3 cells/ul diluted in the thrombin component of fibrin glue (tiseel, baxter) will be applied to the debrided corneal stroma. a soft bandage contact lens will be placed over the cornea at the end of the procedure. the patient will receive topical antibiotic and steroid eye drops in the post-operative period. periodic comprehensive ophthalmic evaluation along with anterior segment optical coherence tomography (asoct) scanning and slit-lamp photography will be done at day 1, day 7, day 45 and day 90.

Eligibility criteria:
inclusion criteria: 1. male and female participants who are aged between 18-60 years. 2. patients who are having with unilateral blindness due to superficial (defined as involving the anterior 200 microns of the corneal stroma on asoct imaging) corneal wounds, ulcers, burns and scars. 3. eyes with otherwise normal. exclusion criteria: 1. active infection, proven by microbiology. 2. unknown etiology, post-herpetic eye disease or eyes with active intra-ocular inflammation. 3. children (\<18 years of age). 4. inability/refusal to give written informed consent or to undergo any of the anterior segment imaging tests.
chewing gum and cognitive function

Conditions: Cognitive Dysfunction

Summary: this study is to investigate whether the improvement or maintenance of cognitive function is superior to the control group when gum chewing is performed in elderly people with subjective cognitive decline or mild cognitive impairment.

the intervention group chew one unscented gum provided by the study for 12 weeks. using kakaotalk, the coordinator sends a chewing gum alarm. the participants are instructed to masticate a gum for 20 minutes every day, alternately for 10 minutes on the right side and 10 minutes on the left side. after chewing gum, they perform masticatory muscle stretching and tongue exercises. after they finish chewing the gum, he or she reports completion by posting an authentication photo in the kakaotalk chat room. the research coordinator checks the certification on a weekly basis and sends a separate phone call to encourage participants who do not chew gum more than twice a week.

Eligibility criteria:
inclusion criteria: * 60 to 79 years of age * all posterior teeth are evenly occluded on both sides, and those who have lost 4 or less teeth in the posterior teeth * those who scored 50 points or less on the periodontal disease self-checklist * meet the diagnostic criteria for subjective cognitive decline or mild cognitive impairment * provide written informed consent exclusion criteria: * those who have difficulty in chewing due to toothache, periodontal disease, temporomandibular joint disease, severe malocclusion, shaking teeth, etc. * those who wear dentures on the upper or lower teeth * dementia * major psychiatric illness such as major depressive disorders * other neurodegenerative disease (e.g., parkinson's disease) * other serious or unstable medical disease such as acute or severe asthma, active gastric ulcer, severe liver disease, or severe renal disease, or any medical conditions preventing to complete the study as judged by the study physician * severe loss of vision, hearing, or communicative disability * significant laboratory abnormality that may result in cognitive impairment * any conditions preventing cooperation as judged by the study physician * coincident participation in any other intervention trial * those who are planning dental treatment such as preservation, prosthetics, and implants during the research period
ptp1b implication in the vascular dysfunction associated with obstructive sleep apnea

Conditions: Sleep Apnea; Inflammation; Atherosclerosis

Summary: obstructive sleep apnea (osa) syndrome is associated with increased vascular dysfunction and atherosclerosis. especially, it has been shown that osa associated intermittent hypoxia represents a pro inflammatory stimulus resulting in macrophage polarization. protein tyrosine phosphatase 1b (ptp1b) is a negative regulator of insulin signaling pathways involved in atherosclerosis. it has been shown that myeloid ptp1b deficiency protects against atherosclerosis. as hypoxia has also been shown to increase ptp1b expression and activity, this study will evaluate the myeloid ptp1b expression and activity in patients with osa as compared to controls and will investigate myeloid ptp1b involvement in the vascular pro inflammatory precess described in osa.


Eligibility criteria:
inclusion criteria: * overnight polysomnographic recording for suspected osa * apnea hypopnea index ≥ 15 per hour for osa patients * apnea hypopnea index \< 15 per hour for non osa patients exclusion criteria: * past history of cardiovascular diseases * diabetes * dyslipidemia * hypertension * obesity (body mass index \> 35 kg/m2 * past history or ongoing inflammatory diseases * cognition impairment

Keywords: ptp1b macrophage
effectiveness of sms reminders on influenza vaccination coverage in patients with ra in the art registry

Conditions: Rheumatoid Arthritis

Summary: biotherapies have significantly improved the prognosis of rheumatoid arthritis (ra), particularly anti-tnf. however, these molecules are associated with a well-demonstrated increase in infectious risk, including an over-risk of pneumococcal and influenza infection.. therefore, when initiating anti-tnf treatments, it is recommended to update the vaccination schedule of these patients, to vaccinate them against pneumococcus and carry out an annual anti influenza vaccination.. however, vaccination coverage remains sub-optimal. the means to improve this vaccination coverage are multiple but often require human resources. medical teams often lack time, nursing interventions are effective but again requires the availability of the health care team. the use of modern digital means (automatic reminders) is an attractive alternative to increase immunization coverage without the use of medical or paramedical time. the objective of the study is to evaluate the effectiveness, in terms of immunization coverage, of sms and/or email reminders reminding the need to vaccinate against seasonal influenza compared to usual care, in patients with ra on biotherapies participating in the e-cohort of the french art registry (nct03062865). this study will be based on the art registry e-cohort. this will be a randomized controlled trial in patients in the art e-cohort. the patients will be allocated in one of the 2 arms : one arm receiving reminders by email and sms of the influenza vaccination, the other arm with absence of reminders. this study will be conducted during the annual french national communication campaign to encourage influenza vaccination. the main evaluation criterion will be the influenza vaccination coverage rate at the end of the vaccination campaign. it will be compared between the two arms.

design : randomised, controlled trial within the e-cohort population of the french art registry (observational study) target population : all participants to the e-cohort of the french art registry (rheumatoid arthritis and anti-tnf)

Eligibility criteria:
all patients included in the french art registry (rheumatoid arthritis and anti-tnf) and participating to the e-cohort. inclusion criteria: * adult patients with ra, * patient in whom the specialist physician decides to start treatment with an anti-tnf drug, regardless of the treatment line and regardless of the anti-tnf, including infliximab, adalimumab, etanercept, certolizumab and golimumab, and their respective biosimilar according to their arrival on the market * clinicians (hospital-based and private practice) who agree to adhere to the yearly renewal of the hospital prescription exclusion criteria: * patient already treated by the same anti-tnf in the past (same drug)

Keywords: anti-tnf flu influenza vaccination biologics bdmards targeted therapies
a trial of abi-007 in patients with advanced non-hematologic malignancies

Conditions: Neoplasms; Metastases, Neoplasm

Summary: this trial will treat patients with advanced (metastatic) cancer with a new chemotherapeutic agent that may be more readily tolerated than some standard therapies. patients will be given the new chemotherapeutic medicine once a week, by intravenous route, for three weeks, followed by a rest week. treatment will be repeated in four week cycles if the patient improves on the therapy, and if there are no adverse events that require withdrawal of medication.

this will be a dose-escalating study. abi-007 will be administered as an outpatient infusion for three weeks followed by a week of rest. the treatment course will repeat every 28 days. no pretreatment will normally be considered necessary. patients will have white blood cell and platelet counts monitored as will indications of performance (karnofsky performance status), and will be asked to describe adverse events, if present. patients will be treated for a minimum of two cycles to be evaluable for the study, and may continue in the study for four cycles within the study, if tumor response and safety parameters warrant continuing. patients may continue on study medication beyond this at the investigator's discretion.

Eligibility criteria:
* at least 18 years of age * life expectancy of at least 2 months * off all therapy for at least 3 weeks prior to study drug administration * biopsy-proven diagnosis of advanced malignancy * patients with solid tumors who have failed standard therapy * karnofsky performance status of 70% or 0-2 swog performance status * hemoglobin at least 9 * white blood cell count of at least 3000/mm3 with absolute neutrophil count of at least 1500/mm3 * platelet count of at least 100,000/mm3 * serum creatinine less than 2 mg/dl * transaminases less than 3x the upper limit of normal * patient must provide informed consent * serum bilirubin less than 1.5 mg/dl

Keywords: cancer solid tumor advanced malignancy taxane therapy biopsy-proven diagnosis of advanced malignancy various solid tumors which are refractory
impact of gut microbiota and tryptophan metabolites on acute pain in lumbar disc herniation surgery patients

Conditions: Microbial Substitution; Tryptophan Metabolism Alterations; Postoperative Pain, Acute

Summary: it is well-established that the gut microbiota plays a crucial role in various pain mechanisms, including visceral pain, inflammatory pain, headache, neuropathic pain, and opioid tolerance. changes in the gut microbiome can alter pain perception. in our study, the investigator investigated the effects of microbiota alterations and the associated tryptophan metabolites on acute pain using the visual analog scale (vas).

the study included patients aged 18 and above undergoing lumbar disc herniation surgery. blood samples were collected preoperatively, at 8 hours, and at 24 hours postoperatively to analyze tryptophan metabolites (picolinic acid, 3- hydroxykynurenine, anthranilic acid, kynurenine, quinolinic acid, kynurenic acid, xanthurenic acid). concurrent vas pain assessments were conducted, and correlations between tryptophan metabolites and vas were evaluated.

Eligibility criteria:
inclusion criteria: * patients undergoing lumbar disc herniation surgery at dokuz eylül university hospital. * patients who have read and consented to the informed consent form for the study. * age 18 years or older. * surgery duration exceeding 2 hours. exclusion criteria: * patients are unwilling to participate in the study. * surgery duration less than 2 hours. * patients under the age of 18. * patients with a history of abdominal surgery. * patients who received antibiotic therapy for intestinal pathology within the last 3 weeks. * patients with known abdominal pathologies suspected to alter the microbial flora (e.g., crohn's disease, ulcerative colitis, celiac disease).

Keywords: microbiota tryptophan picolinic acid kynurenic acid xanthurenic acid quinolinic acid acute pain
efficacy study of neoadjuvant chemotherapy with chemoradiation therapy for nasopharyngeal carcinoma

Conditions: Chemoradiation; Nasopharyngeal Carcinoma

Summary: locally advanced nasopharyngeal carcinoma patients(uicc7th stageiii to ivb) will receive either cisplatin plus 5-fluorouracil (pf) or docetaxel plus cisplatin and 5-fluorouracil(tpf) neoadjuvant chemotherapy with concurrent chemoradiation.

for locally advanced nasopharyngeal carcinoma patients(uicc7th stageiii to ivb),the investigators randomised assign to either 3 cycles of cisplatin plus 5-fluorouracil plus (pf) or 3 cycles of docetaxel plus cisplatin and 5-fluorouracil(tpf) neoadjuvant chemotherapy. 21 days a cycle. after the neoadjuvant chemotherapy ,the patients will receive the intensity modulated radiotherapy(imrt) with 2 cycles of concurrent chemotherapy of cisplatin 80mg/m2.

Eligibility criteria:
inclusion criteria: 1. patients with newly histologically confirmed non-keratinizing carcinoma. 2. tumor staged as n2-3 or t3-4n1(according to the 7th ajcc staging system) 3. no evidence of distant metastasis(m0) 4. performance status:kps\>70 5. with normal liver function test(alt, ast\<1.5uln) 6. renal:creatinine clearance \>60ml/min 7. without hematopathy,marrow:wbc\>4\*109/l, hgb\>80g/l, and plt\>100\*109/l. 8. with controled blood glucose for diabetes patients 9. written informed consent exclusion criteria: 1. who type i squamous cell carcinoma or adenocarcinoma 2. age\>70 or \<18 3. with a history of renal disease 4. prior malignancy (except adequately treated carcinoma in-situ of the cervix or basal/squamous cell carcinoma of the skin0 5. previous chemotherapy or radiotherapy(except non-melanomatous skin cancers outside the intended rt treatment volume) 6. patient is pregnant or lactating . 7. peripheral neuropathy 8. emotional disturbance

Keywords: nasopharyngeal carcinoma (npc) cisplatin and 5-fluorouracil (pf) docetaxel,cisplatin and 5-fluorouracil(tpf) neoadjuvant chemotherapy intensity modulated radiotherapy(imrt)
effect of probiotic drink on number of salivary mutans streptococci in school going children

Conditions: Dental Caries

Summary: this study was conducted to assess the effects of commercially available probiotic drink on the number of salivary mutans streptococci in school going children, aged 12-14 years in bangalore city in india

probiotic bacteria are thought to reduce the risk of diseases in oral cavity, namely dental caries. studies have suggested that oral cavity can benefit immensely from these friendly bacteria, although more clinical trials are needed to establish concrete results. hence, this study was undertaken as a 6 month clinical trial to assess the effects of probiotic on the most frequent resident of oral micro flora- the mutans streptococci. method- design: parallel arm design sample size: 60 subjects (30 subjects in each group) duration: 6 months material used- intervention/manipulation: 50ml commercially available probiotic drink for one group (30 subjects in study group) and 50 ml of plain, unsweetened and unflavored milk to control group (30 subjects in control group)for a period of 6 months. indices used: plaque index- turskey gilmore-glikman modification of quigley-hein, plaque index (1970) gingival index-loe.h and silness p. gingival index (1963) both the indices were used twice, at the start of the study, that is, to collect base line data and at the end of the intervention period (6 months)as final data collected. sample collection: stimulated saliva was collected (5ml) and analyzed for cfu of streptococcus mutans and lactobacilli at the start of the study and after 6 months, at the end of the intervention. statistical analysis: students t test, fisher exact test and chi-square test were used to compare the baseline data with the final data collected at the end of the intervention.

Eligibility criteria:
inclusion criteria: * no active carious lesion * restored dental cavities * on no systemic antibiotic medication 6 weeks before commencing the study exclusion criteria: * habitual consumers of probiotics or xylitol chewing gums * recent exposure to topical/ systemic fluoride treatment * undergoing any orthodontic treatment during the entire study tenure

Keywords: probiotics, streptococcus mutans, lactobacilli, plaque index, gingival index